Search research articles
Contact Us
Filters
Showing results (201-210 of 271) with videos related to
Page
of 28
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
November 29, 2024
Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients
C Robert, G V Long, J Larkin, et al.
Frontiers in Immunology
|
January 19, 2024
MediMer: a versatile do-it-yourself peptide-receptive MHC class I multimer platform for tumor neoantigen-specific T cell detection
Marten Meyer, Christina Parpoulas, Titouan Barthélémy, et al.
British Journal of Cancer
|
February 14, 2018
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients
Markus Hecht, Friedegund Meier, Lisa Zimmer, et al.
The British Journal of Dermatology
|
February 18, 2020
GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma
E Livingstone, A Zaremba, S Horn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 12, 2025
Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
Takami Sato, Marcus O Butler, Sophie Piperno-Neumann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2017
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
Sandra P D'Angelo, James Larkin, Jeffrey A Sosman, et al.
JAMA Oncology
|
December 4, 2015
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B Johnson, Ryan J Sullivan, Patrick A Ott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 23, 2026
IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma
J C Hassel, A Arance, M S Carlino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 19, 2025
Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma
Reinhard Dummer, Shahneen Sandhu, Wilson H Miller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 1, 2016
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
A M Menzies, D B Johnson, S Ramanujam, et al.
Page
of 28
Search research articles
Search
Showing results (201-210 of 271) with videos related to
Sort By:
Page
of 28
European Journal of Cancer (Oxford, England : 1990)
|
November 29, 2024
Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients
C Robert, G V Long, J Larkin, et al.
Frontiers in Immunology
|
January 19, 2024
MediMer: a versatile do-it-yourself peptide-receptive MHC class I multimer platform for tumor neoantigen-specific T cell detection
Marten Meyer, Christina Parpoulas, Titouan Barthélémy, et al.
British Journal of Cancer
|
February 14, 2018
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients
Markus Hecht, Friedegund Meier, Lisa Zimmer, et al.
The British Journal of Dermatology
|
February 18, 2020
GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma
E Livingstone, A Zaremba, S Horn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 12, 2025
Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
Takami Sato, Marcus O Butler, Sophie Piperno-Neumann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2017
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
Sandra P D'Angelo, James Larkin, Jeffrey A Sosman, et al.
JAMA Oncology
|
December 4, 2015
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B Johnson, Ryan J Sullivan, Patrick A Ott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 23, 2026
IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma
J C Hassel, A Arance, M S Carlino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 19, 2025
Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma
Reinhard Dummer, Shahneen Sandhu, Wilson H Miller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 1, 2016
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
A M Menzies, D B Johnson, S Ramanujam, et al.
Page
of 28